Recently, the American Institute for Medical and Biological Engineering ("AIMBE") announced the list of 153 newly elected fellows from around the world in 2022 in recognition of their achievements in medical and biological engineering. outstanding achievements.
According to statistics from Leifeng.com, 39 Chinese scholars have been elected, accounting for 25%.
Fellowship of the American Academy of Medical and Biological Engineering (AIMBE Fellow) is one of the highest professional honors in the field of medical and biological engineering.
Currently, AIMBE Fellow members include 3 Nobel Prize winners, 18 members who have won the Presidential Medal for Science, Technology and Innovation, 201 members of the National Academy of Engineering, 101 members of the National Academy of Sciences and 45 members. Member of the U.S. National Academy of Sciences.
The following is a list of scholars working in domestic institutions:
Chen Xuesi
Chen Xuesi, academician of the Chinese Academy of Sciences, executive deputy director of the Academic Committee of Changchun Institute of Applied Chemistry, Chinese Academy of Sciences , doctoral supervisor, deputy director of the academic committee of the Key Laboratory of Ecological and Environmental Polymer Materials, Chinese Academy of Sciences, and leader of the biopolymer research group.
After graduating from the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences in 1988 with a master's degree, he stayed at the institute to work. He then received a doctorate from Waseda University and engaged in postdoctoral research at the University of Pennsylvania in the United States.
In 1999, Chen Xuesi returned to work at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, and served successively as a researcher and doctoral tutor, engaged in biodegradable medical polymer materials, tissue engineering and drug sustained release, polylactic acid and poly(lactic acid). -Research and development work in the industrialization of caprolactone and other directions.
In 2016, Chen Xuesi was elected as a fellow of the International Federation of Biomaterials and Engineering, and in 2019, he was elected as an academician of the Chinese Academy of Sciences.
Chen Xuesi has served as the project leader for the “Thirteenth Five-Year Plan” key R&D projects of the Ministry of Science and Technology, the National Natural Science Foundation of China Basic Research Center project, etc. In cooperation with Zhejiang Hisun Group, we have realized the industrialization of 15,000 tons of polylactic acid, and our technical level has reached an internationally leading level.
Reasons for selection: Contributions to the development of biodegradable polymers for gene and drug delivery, nanomedicine, tissue engineering, and large-scale production and commercialization.
Ma Guanghui
Ma Guanghui, academician of the Chinese Academy of Sciences, researcher and doctoral supervisor of the Institute of Process Engineering, Chinese Academy of Sciences, director of the State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, and National Biochemical Engineer Director of the Engineering Technology Research Center (Beijing), Vice Chairman of the Chinese Particle Society, Vice Chairman of the Biochemical Engineering Committee of the Chinese Chemical Society, and Director of the Chinese Bioengineering Society.
In 1984, Ma Guanghui was sent by the government to study abroad in Gunma University, Japan, and obtained a bachelor's degree in fiber polymer engineering; in 1990 and 1993, he obtained a master's degree and a doctorate in polymer engineering from Tokyo Institute of Technology respectively.
After receiving his Ph.D., Ma Guanghui served as an assistant professor at the Graduate School of Applied Science of Biosystems, Tokyo University of Agriculture and Technology. After returning to China in 2001, he was selected into the "Hundred Talents Program" of the Chinese Academy of Sciences and served as a researcher and doctoral supervisor at the Institute of Process Engineering, Chinese Academy of Sciences.
After returning to China, Ma Guanghui was mainly engaged in the preparation of uniform biological microspheres and microcapsules and their application in biochemical engineering and medical engineering, researching and developing protein/vaccine separation media, sustained and controlled release drug carriers, Innovative products such as immune adjuvants (vaccine delivery systems), cell culture microcarriers, and enzyme immobilized carriers.
According to the Institute of Process Engineering of the Chinese Academy of Sciences, Ma Guanghui*** has obtained 88 Chinese invention patent authorizations and 12 international patent authorizations. The patented technology and products have been applied by more than 500 units at home and abroad.
Reason for selection: Contributions to bioengineering through innovative membrane emulsification technology and particle system design for biomedical formulations.
Nie Guangjun
Nie Guangjun, Distinguished Researcher of the Chinese Academy of Sciences, Distinguished Professor of the National University of Science and Technology, Chief Scientist of the National Major Scientific Research Plan Project on Nano Research of the Ministry of Science and Technology, Chief Scientist of the National Key R&D Plan, Chinese Biophysical Society Executive director, member of the Nano-Oncology Professional Committee of the Chinese Anti-Cancer Association, and member of the Nano-medicine Professional Committee of the Chinese Pharmaceutical Association.
In 2002, Nie Guangjun received his PhD from the Institute of Biophysics, Chinese Academy of Sciences, and then engaged in postdoctoral research at McGill University in Canada.
After returning to China in 2008, he established the "Nanobiology and Nanobiomaterials" laboratory at the National Nanoscience Center and established a multidisciplinary interdisciplinary research team. The research areas mainly include tumor nanobiology, nanobiology and nanotechnology. Biotechnology and nanobiological effects, etc.
According to the National Nanoscience Center, Nie Guangjun *** has applied for more than 40 invention patents related to anti-tumor applications (more than 20 authorized Chinese patents, 3 authorized patents in the United States, 1 Japanese patent, patent transfer 2 items).
Reason for selection: Make outstanding contributions to the development of nanomedicines that regulate tumor microenvironment and intelligent anti-tumor nanorobots.
Gao Weiqiang
Gao Weiqiang is currently the "Wang Kuancheng" Chair Professor and doctoral supervisor at Shanghai Jiao Tong University, director of the State Key Laboratory of Oncogenes and Related Genes, and School of Biomedical Engineering Chairman, Vice President of Med-X Research Institute, Director of Med-X-Renji Hospital Stem Cell Research Center.
In 1982, Gao Weiqiang graduated from Nanjing University with a bachelor's degree. In the same year, he entered the Chinese Academy of Sciences as a graduate student and was selected for the CUSBEA project. He went to the United States in 1983 and received a doctorate from Columbia University in 1989. He completed postdoctoral research at Columbia University School of Medicine and Rockefeller University. . From 1993 to 2010, he served as scientist/laboratory director and senior scientist of Genentech Corporation in the United States. During this period, he was awarded the "Overseas Outstanding Young Scholar" by the National Natural Science Foundation of China in 2003.
Returned to China full-time in 2010. Served as the director of the Stem Cell Research Center of Yanji Hospital. He is currently undertaking the National Key Scientific Research Plan Project of the Ministry of Science and Technology and the key and general projects of the National Natural Science Foundation. He is also the person in charge of the key subject of oncology of the Shanghai Municipal Education Commission and the key subject of clinical oncology of the Shanghai Municipal Health and Family Planning Commission.
Gao Weiqiang has long been committed to the research on the mechanisms of "stem cells and tissue development and repair" and "tumor occurrence and development (including cancer stem cells)". In recent years, it has focused on the exploration of cancer stem cells, drug resistance, diagnosis and targeted therapy, as well as research on nerve damage repair and inner ear hair cell development and regeneration.
Reason for selection: Contributions to stem cells, tissue regeneration, and translational medicine for degenerative diseases and cancer stem cells.
Zhang Can
Zhang Can is the dean and doctoral supervisor of the Institute of Pharmaceutical Sciences of China Pharmaceutical University, and the director of the High-end Pharmaceutical Preparation and Materials Research Center. He is also the deputy editor-in-chief of Biomaterials Science, a journal of the Royal Society of Chemistry, a standing committee member of the Biomedical Composite Materials Branch of the Chinese Society of Composite Materials, a member of the Nanomedicine Professional Committee of the Chinese Pharmaceutical Society, a member of the Academic Committee of Tianjin Key Laboratory of Clinical Drug Key Technologies, and the Journal of China Pharmaceutical University Editorial board member and member of the Academic Committee of China Pharmaceutical University.
In 1986, Zhang Can received a bachelor's degree in polymer synthetic materials from the Department of Chemistry, Nanjing University; a master's degree in medicinal chemistry from China Pharmaceutical University in 2000; and a master's degree in polymer chemistry and physics from the School of Chemistry and Chemical Engineering, Nanjing University in 2003. PhD. Since starting his career, he has been engaged in the research of new medicinal polymer materials and innovative drugs.
Served as the project leader in charge of the Ministry of Science and Technology’s major new drug creation projects, key technology sub-projects of the new drug creation major projects, the Ministry of Science and Technology’s key international exchange projects, the 863 Program, the National Natural Science Foundation of China’s key and general projects, and education He has more than 40 scientific research projects, including key projects of the Ministry of Education, and has obtained 24 authorized invention patents. He has been the main translator of 1 book and co-editor of 3 books.
Reason for selection: Contributions to cell therapy and translational research.
Wang Meiyun
Wang Meiyun, director of Henan Provincial Medical Imaging Center.
Doctor, chief physician, professor, doctoral supervisor, postdoctoral fellow at Harvard Medical School, visiting professor at Johns Hopkins Medical School, the first certified lecturer in the International Society of Magnetomyology in China, and one of the first batch of Chinese imaging lecturers trained by the American College of Radiology personnel.
Wang Meiyun’s research interests include imaging diagnosis and research of neurological diseases and the application of new magnetic resonance imaging techniques. She has edited 1 "English Course for Medical Imaging" and participated in the editing of 8 monographs. In recent years, he has successively won the honorary titles of National Outstanding Science and Technology Workers, Henan Province Academic and Technology Leaders, Henan Province Outstanding Young Science and Technology Experts, and Henan Provincial Government Special Allowance Experts.
Reason for selection: Contribution to exploring and expanding the value of multi-modal imaging technology in improving disease diagnosis and treatment.
Raymond Kai-yu Tong
Raymond Kai-yu Tong is an academician of the American Academy of Medicine and Biological Engineering, a founding academician of the Hong Kong Young Academy of Sciences, and the director of the Department of Biomedical Engineering at the Chinese University of Hong Kong.
In 1999, Tang Qiyu received a PhD in biomedical engineering from the University of Strathclyde, UK. His research fields include rehabilitation robots, brain-computer interfaces (BCI), neural engineering, functional electrical stimulation (FES) and stroke research. Mouse model, etc.
In 2013, he won the Top Ten Outstanding Youth (Hong Kong) Award, and his research results won the gold medal at the 44th International Exhibition of Inventions of Geneva. In 2016, he was invited to attend the Davos Forum to give a technical report.
Reason for selection: Developed the "Hand of Hope" upper limb rehabilitation device for stroke rehabilitation, and established the first biomedical engineering department in Hong Kong.
Yao Jianhua
Yao Jianhua, chief scientist of AI medical care at Tencent AI Lab, holds an undergraduate degree in computer science from Tianjin University, a master's degree in computer science from Tsinghua University, and a degree from The Johns Hopkins University in the United States. in computer science from Johns Hopkins University.
Yao Jianhua has achieved outstanding results in precision medicine, image analysis, pathological image processing, tumor growth prediction, and surgical navigation. At the same time, Yao Jianhua serves as the deputy editor-in-chief of IEEE JBHI, responsible for editing multiple special issues on AI imaging, serving as the Area Chair for multiple top AI conferences, and organizing multiple international academic seminars on medical imaging. He has published more than 350 papers in international journals and top conferences, been cited more than 14,000 times, and has an h-index of 47.
Since joining Tencent AI Lab, Yao Jianhua has led the team to release a number of research and application results, including China’s first smart microscope approved for clinical application; providing Tencent’s national imaging product “Tencent Miying” Technology and solutions; the COVID-19 severity prediction model developed in collaboration with Zhong Nanshan’s team was published in Nature Communication and used in more than 80 countries around the world. In the future, Yao Jianhua will also lead the team to delve into the direction of AI + life sciences.
Reason for selection: Contribution to research, clinical services and commercial development in the field of biomedical image analysis and artificial intelligence healthcare.
The list of all selected Chinese is as follows:
Chen Xuesi, Chinese Academy of Sciences
Ma Guanghui, Chinese Academy of Sciences
Nie Guangjun, National Center for Nanoscience and Technology
Gao Weiqiang, Shanghai Jiao Tong University
Zhang Can, China Pharmaceutical University
Wang Meiyun, Director, Henan Provincial People's Hospital
Tang Qiyu, University of Hong Kong
Tencent AI Lab Yao Jianhua
Abbott Qiaoqiao Ruan
Abbott Tao Xin
University of Delaware Liyun Wang
Beth Israel Deaconess Healthcare Center Wenyi Wei
Northwestern University Hao F. Zhang
OncoC4 Pan Zheng
Washington University in St. Louis Quing Zhu
Siemens Healthcare Rui Liao
Jian Ma, Carnegie Mellon University
Ji Chen, University of Houston
Wei R Chen, University of Oklahoma
Delaware University Wilfred Chen
University of Pennsylvania Youhai H. Chen
University of Missouri-Columbia Jianlin Cheng
Southern Methodist University Jung-Chih Chiao
< p> Zhaohua Ding, Vanderbilt UniversityYizhou Dong, Ohio State University
Jean Gao, University of Texas at Arlington
Gang Han, University of Massachusetts Medical School < /p>
Xue Han, Boston University
Shuiwang Ji, Texas A&M University
Steve Jiang, University of Texas Southwestern Medical Center
Yuanpei, University of California, Davis Li
Chang Liu, University of California, Irvine
Chunlei Liu, University of California, Berkeley
Wendy Liu, University of California, Irvine
Harvard Xiaole S. Liu, Dana-Farber Cancer Institute, University College of Medicine
Ting Lu, University of Illinois at Urbana-Champaign
Dacheng Ren, Syracuse University
Stephen T. Wong, Houston Methodist Hospital
Nianqiang Wu, University of Massachusetts Amherst